Genis
Genis is an Icelandic biotechnology company founded in 2005, specializing in the development and application of therapeutic chitin derivatives. The company's mission is to deliver products that improve quality of life by harnessing the regenerative mechanisms developed by nature. Genis focuses on innovative solutions across three product platforms: orthobiologics for bone regeneration, pharmaceutical development for novel drugs, and dietary supplements for human and animal applications. With a strong research background and significant investment in R&D, Genis aims to address unmet medical needs in inflammatory diseases and bone regeneration.
Industries
Nr. of Employees
small (1-50)
Products
Chitooligosaccharide drug candidates (short-chain ChOS APIs)
Series of short-chain chitooligosaccharide APIs produced from chitin feedstock, designed to modulate the C/CLP system and provide anti-inflammatory effects via direct anti-inflammatory mechanisms and binding of chitinase-like proteins.
Polymeric chitosan biomaterial for tissue regeneration
A polymeric chitosan-based biomaterial engineered to stimulate bone tissue formation and partially degrade in vivo to release shorter-chain oligosaccharides with regenerative and anti-inflammatory properties.
Injectable resorbable bone graft substitute
Injectable bone graft formulation designed to be resorbed over time while stimulating new bone formation; demonstrated osteogenic and osteoconductive properties in ovine tibia studies.
3D-printed bioactive bone scaffolds
High-resolution additive-manufactured scaffolds constructed from chitosan-derived biomaterials to provide tailored geometry, biological induction and mechanical support for bone repair.
Bioactive implant coatings using chitosan-based material
Coating technology to apply chitosan-derived biomaterial to metal implants to encourage tissue integration and leverage antimicrobial properties to mitigate post-implant complications.
Chitosan-derived dietary supplement (human)
A natural dietary supplement derived from short-chain chitosan marketed for support of musculoskeletal comfort and activity in adults.
Chitooligosaccharide drug candidates (short-chain ChOS APIs)
Series of short-chain chitooligosaccharide APIs produced from chitin feedstock, designed to modulate the C/CLP system and provide anti-inflammatory effects via direct anti-inflammatory mechanisms and binding of chitinase-like proteins.
Polymeric chitosan biomaterial for tissue regeneration
A polymeric chitosan-based biomaterial engineered to stimulate bone tissue formation and partially degrade in vivo to release shorter-chain oligosaccharides with regenerative and anti-inflammatory properties.
Injectable resorbable bone graft substitute
Injectable bone graft formulation designed to be resorbed over time while stimulating new bone formation; demonstrated osteogenic and osteoconductive properties in ovine tibia studies.
3D-printed bioactive bone scaffolds
High-resolution additive-manufactured scaffolds constructed from chitosan-derived biomaterials to provide tailored geometry, biological induction and mechanical support for bone repair.
Bioactive implant coatings using chitosan-based material
Coating technology to apply chitosan-derived biomaterial to metal implants to encourage tissue integration and leverage antimicrobial properties to mitigate post-implant complications.
Chitosan-derived dietary supplement (human)
A natural dietary supplement derived from short-chain chitosan marketed for support of musculoskeletal comfort and activity in adults.
Services
API development for inflammatory diseases
Research and development of short-chain chitooligosaccharide active pharmaceutical ingredients aimed at modulating the C/CLP system for conditions such as rheumatoid arthritis, COPD and asthma.
Orthobiologic medical device development
Development of chitosan-based orthobiologic products including injectable bone graft substitutes, 3D-printed scaffolds and bioactive implant coatings to promote bone tissue formation.
Dietary supplement formulation and commercialization
Formulation, market launch and distribution support for natural chitosan-derived supplements for human and animal health applications.
Preclinical testing and validation
Conduct of preclinical safety and efficacy studies in animal models (including sheep tibia models) and management of early clinical study activities.
Licensing and commercialization support
Commercialization via licensing agreements for veterinary products and support for market entry in international markets.
API development for inflammatory diseases
Research and development of short-chain chitooligosaccharide active pharmaceutical ingredients aimed at modulating the C/CLP system for conditions such as rheumatoid arthritis, COPD and asthma.
Orthobiologic medical device development
Development of chitosan-based orthobiologic products including injectable bone graft substitutes, 3D-printed scaffolds and bioactive implant coatings to promote bone tissue formation.
Dietary supplement formulation and commercialization
Formulation, market launch and distribution support for natural chitosan-derived supplements for human and animal health applications.
Preclinical testing and validation
Conduct of preclinical safety and efficacy studies in animal models (including sheep tibia models) and management of early clinical study activities.
Licensing and commercialization support
Commercialization via licensing agreements for veterinary products and support for market entry in international markets.
Expertise Areas
- Orthobiologics and bone regeneration
- Therapeutic oligosaccharide drug development
- Biomaterials formulation (chitosan-based)
- 3D printing for medical implants
Key Technologies
- Chitin deacetylation and enzymatic degradation
- Chitooligosaccharide synthesis and fractionation
- Polymeric chitosan biomaterials
- Injectable resorbable bone graft formulations